Skip to main content
. 2016 Aug 1;7(35):57077–57085. doi: 10.18632/oncotarget.10976

Figure 1. A. Clinical-pathological characteristics of melanoma patients and tumours and relation to COX-2 expression.

Figure 1

Frequencies are indicated in absolute values (percentage). COX-2 median expression values, where indicated with (−), include negative samples and samples with low COX-2 expression (≤9%); where indicated with (+) include samples with high COX-2 expression (≥10%). Abbreviations: pT (primary tumour), M (male), F (female), Y (present), N (not present). B-D. Immunohistochemistry staining of COX-2 and Kaplan–Meier progression free survival curve stratified by median of COX-2 expression. B. Immunohistochemistry staining of COX-2: left panel COX-2 negative expression; right panel COX-2 positive expression. Images are 20x. C. Kaplan–Meier progression free survival (PFS) curve of cases under the median of COX-2 expression stratified by not expressed (0%; n=12; blue line) and low COX-2 expression (≤9%; n=5 green line) shows a not significant trend in PFS reduction. D. Kaplan–Meier PFS curve of cases stratified by low COX-2 expression (≤9%; n= 17; blue line), and high COX-2 expression (≥10%; n=22; green line). Kaplan–Meier curve illustrate a significant correlation between COX-2 high expression and PFS. E-F. COX-2 expression and BRAFV600E and NRASQ61 mutational status. (E) Absence of correlation between COX-2 expression and BRAFV600E mutational status. (F) Absence of correlation between COX-2 expression and NRASQ61 mutational status. Data are expressed as BOX-plot distribution.